| Nov 15 |
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative
|
| Nov 8 |
Kiora Pharmaceuticals GAAP EPS of -$0.81 misses by $0.05
|
| Nov 8 |
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
|
| Oct 30 |
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
|
| Oct 29 |
Kiora Pharmaceuticals gets approval to initiate mid-stage trial for eye disorder treatment
|
| Oct 29 |
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa
|
| Aug 9 |
Kiora Pharmaceuticals GAAP EPS of -$0.53 beats by $0.33
|
| Aug 9 |
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
|
| Jul 30 |
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies
|
| Jul 10 |
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation
|
